Abstract
With ever-increasing drug resistant clinical isolates, novel antibiotics with new targets are urgently needed. Tuberculosis, caused by Mycobacterium tuberculosis, showed formidable antibiotics resistance. InhA, the enoyl-acyl carrier protein (ACP) reductase involved in the type II fatty acid synthesis pathway (FASII) in Mycobacterium tuberculosis, represents an appealing target for the development of new anti-tuberculosis (TB) agents. Inhibitors against InhA might be ideal lead or antibiotics. The latest development of InhA inhibitors is summarized in this paper.
Keywords: Drug discovery, drug resistance, enoyl-ACP reductase, InhA, isoniazid, tuberculosis.
Letters in Drug Design & Discovery
Title:Progress on the Discovery of Inhibitors of InhA, the FAS II Enoyl-ACP Reductase TB Drug Discovery Targeted on InhA
Volume: 13 Issue: 6
Author(s): Yi Zhang, Longxiang Xie and Jianping Xie
Affiliation:
Keywords: Drug discovery, drug resistance, enoyl-ACP reductase, InhA, isoniazid, tuberculosis.
Abstract: With ever-increasing drug resistant clinical isolates, novel antibiotics with new targets are urgently needed. Tuberculosis, caused by Mycobacterium tuberculosis, showed formidable antibiotics resistance. InhA, the enoyl-acyl carrier protein (ACP) reductase involved in the type II fatty acid synthesis pathway (FASII) in Mycobacterium tuberculosis, represents an appealing target for the development of new anti-tuberculosis (TB) agents. Inhibitors against InhA might be ideal lead or antibiotics. The latest development of InhA inhibitors is summarized in this paper.
Export Options
About this article
Cite this article as:
Zhang Yi, Xie Longxiang and Xie Jianping, Progress on the Discovery of Inhibitors of InhA, the FAS II Enoyl-ACP Reductase TB Drug Discovery Targeted on InhA, Letters in Drug Design & Discovery 2016; 13 (6) . https://dx.doi.org/10.2174/1570180812666151016205422
DOI https://dx.doi.org/10.2174/1570180812666151016205422 |
Print ISSN 1570-1808 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-628X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Structure-based Virtual Screening Approaches in Kinase-directed Drug Discovery
Current Topics in Medicinal Chemistry Editorial [ Carbonic Anhydrases as Drug Targets Executive Editor: Claudiu T. Supuran ]
Current Pharmaceutical Design Gender Disparity in Pediatric Diseases
Current Molecular Medicine Targeting the Folate Receptor: Improving Efficacy in Inorganic Medicinal Chemistry
Current Medicinal Chemistry Synthesis, Characterization and Biological Evaluation Against Influenza Virus Agonists of (N'E,N'"E)-2,2'-[[1,1'-Biphenyl]-4,4'-dihylbis(oxy)]bis (N'-arylmethyleneacetohydrazides)
Letters in Organic Chemistry Effects of Alcohol in the Lung
Current Respiratory Medicine Reviews Demographic, Clinical and Laboratory Profiles of HIV Infected Patients Admitted into Imam Khomeini Hospital of Tehran, Iran
Infectious Disorders - Drug Targets Fungal Production and Manipulation of Plant Hormones
Current Medicinal Chemistry Docking-Related Survey on Natural-Product-Based New Monoamine Oxidase Inhibitors and Their Therapeutic Potential
Combinatorial Chemistry & High Throughput Screening New Approaches for Anti-Infective Drug Discovery: Antibiotics, Vaccines and Beyond
Current Drug Targets - Infectious Disorders Editorial [Hot Topic: Carbonic Anhydrase Inhibitors (Guest Editor: Claudiu T. Supuran)]
Current Topics in Medicinal Chemistry Essential Oils with Microbicidal and Antibiofilm Activity
Current Pharmaceutical Biotechnology Recent Advances in Clinical Immunology, Endocrine & Metabolic Drugs: An Editorial Overview
Clinical Immunology, Endocrine & Metabolic Drugs (Discontinued) Editorial: [A Threat to One is a Threat to All – Biosecurity for the Western World Starts in Developing Countries: Do We Speak the Same Language of Hygiene?]
Inflammation & Allergy - Drug Targets (Discontinued) Recent Applications of Birch Reduction in Total Synthesis of Natural Products
Current Organic Chemistry Mini Heme-Proteins: Designability of Structure and Diversity of Functions
Current Protein & Peptide Science QSPR and Flow Cytometry Analysis (QSPR-FCA): Review and New Findings on Parallel Study of Multiple Interactions of Chemical Compounds with Immune Cellular and Molecular Targets
Current Drug Metabolism Development and Validation of a Fast Reversed Phase Liquid Chromatographic Method for the Analysis of Ethionamide in Dosage Forms
Current Pharmaceutical Analysis The α/β Hydrolase Fold Proteins of Mycobacterium tuberculosis, with Reference to their Contribution to Virulence
Current Protein & Peptide Science Why Antidiabetic Vanadium Complexes are Not in the Pipeline of “Big Pharma” Drug Research? A Critical Review
Current Medicinal Chemistry